ישראל - עברית - Ministry of Health

taro pharmaceutical industries ltd - macrogols; potassium chloride; sodium bicarbonate; sodium chloride - אבקה להכנת תמיסה - macrogols 315.0 g; potassium chloride 1.1175 g; sodium bicarbonate 4.2840 g; sodium chloride 8.4240 g - mineral salts in combination - mineral salts in combination - bowel cleansing prior to colonoscopy and barium enema x-ray examinations.

ישראל - עברית - Ministry of Health

אלקליל בעמ - איפור

ישראל - עברית - Ministry of Health

taro pharmaceutical industries ltd - polyethylene glycol 3350 - אבקה להכנת תמיסה - polyethylene glycol 3350 4 g - macrogol

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - ascorbic acid; macrogols; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate anhydrous - אבקה להכנת תמיסה - potassium chloride 1.015 g; sodium ascorbate 5.9 g; macrogols 100 g; sodium chloride 2.691 g; sodium sulfate anhydrous 7.5 g; ascorbic acid 4.7 g - electrolytes in combination with other drugs - electrolytes in combination with other drugs - for bowel cleansing prior to any clinical procedures requiring a clean bowel e.g. bowel endoscopy or radiology.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - solifenacin succinate - טבליה - solifenacin succinate 5 mg - solifenacin - solifenacin - solifenacin is indicated for symptomatic treatment of urge incontinence and/or urinary frequency and urgency as may occur in patients with overactive bladder syndrome.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - solifenacin succinate - טבליה - solifenacin succinate 10 mg - solifenacin - solifenacin - solifenacin is indicated for symptomatic treatment of urge incontinence and/or urinary frequency and urgency as may occur in patients with overactive bladder syndrome.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - atorvastatin as calcium - טבליה - atorvastatin as calcium 10 mg - atorvastatin - atorvastatin - atorvastatin teva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. atorvastatin teva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - atorvastatin as calcium - טבליה - atorvastatin as calcium 10 mg - atorvastatin - atorvastatin - atorvastatin teva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. atorvastatin teva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - atorvastatin as calcium - טבליה - atorvastatin as calcium 20 mg - atorvastatin - atorvastatin - atorvastatin teva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. atorvastatin teva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - atorvastatin as calcium - טבליה - atorvastatin as calcium 20 mg - atorvastatin - atorvastatin - atorvastatin teva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. atorvastatin teva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl